Related references
Note: Only part of the references are listed.Prevalence and Risk Factors for Major Infections in Patients with Antineutrophil Cytoplasmic Antibody-associated Vasculitis: Influence on the Disease Outcome
Eloi Garcia-Vives et al.
JOURNAL OF RHEUMATOLOGY (2020)
Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group
Antoine Lafarge et al.
RHEUMATOLOGY (2020)
Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis
Michael Walsh et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-Term Rituximab Use to Maintain Remission of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Trial
Pierre Charles et al.
ANNALS OF INTERNAL MEDICINE (2020)
Rituximab for induction and maintenance therapy of granulomatosis with polyangiitis: a single-centre cohort study on 114 patients
Xavier Puechal et al.
RHEUMATOLOGY (2019)
Time-dependent biases in observational studies of comparative effectiveness research in rheumatology. A methodological review
Michele Iudici et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Counterpoint: Keeping the Demons at Bay When Handling Time-Varying Exposures-Beyond Avoiding Immortal Person-Time
Jessie K. Edwards et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2019)
Trimethoprim-sulfamethoxazole prophylaxis prevents severe/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis
Andreas Kronbichler et al.
ANNALS OF THE RHEUMATIC DISEASES (2018)
Clinical characteristics and outcome of Spanish patients with ANCA-associated vasculitides Impact of the vasculitis type, ANCA specificity, and treatment on mortality and morbidity
Roser Solans-Laque et al.
MEDICINE (2017)
Low-dose glucocorticoids plus rituximab versus high-dose glucocorticoids plus rituximab for remission induction in ANCA-associated vasculitis (LoVAS): protocol for a multicentre, open-label, randomised controlled trial
Shunsuke Furuta et al.
BMJ OPEN (2017)
Mortality in ANCA-associated vasculitis: a meta-analysis of observational studies
Ju Ann Tan et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive Granulomatosis With Polyangiitis (Wegener's) Is a Clinically Distinct Subset of ANCA-Associated Vasculitis A Retrospective Analysis of 315 Patients From a German Vasculitis Referral Center
Jan H. Schirmer et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Myeloperoxidase-Antineutrophil Cytoplasmic Antibody (ANCA)-Positive and ANCA-Negative Patients With Granulomatosis With Polyangiitis (Wegener's) Distinct Patient Subsets
Eli M. Miloslavsky et al.
ARTHRITIS & RHEUMATOLOGY (2016)
Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance
K. L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2015)
Treatment of Systemic Necrotizing Vasculitides in Patients Aged Sixty-Five Years or Older
Christian Pagnoux et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Rituximab versus Azathioprine for Maintenance in ANCA-Associated Vasculitis
L. Guillevin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Revisiting the classification of clinical phenotypes of anti-neutrophil cytoplasmic antibody-associated vasculitis: a cluster analysis
Alfred Mahr et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides
J. C. Jennette et al.
ARTHRITIS AND RHEUMATISM (2013)
Infections in vasculitis
Loic Guillevin
BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY (2013)
Classification of antineutrophil cytoplasmic autoantibody vasculitides: The role of antineutrophil cytoplasmic autoantibody specificity for myeloperoxidase or proteinase 3 in disease recognition and prognosis
Sophia Lionaki et al.
ARTHRITIS AND RHEUMATISM (2012)
Long-term patient survival in ANCA-associated vasculitis
Oliver Flossmann et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
The Five-Factor Score Revisited Assessment of Prognoses of Systemic Necrotizing Vasculitides Based on the French Vasculitis Study Group (FVSG) Cohort
Loic Guillevin et al.
MEDICINE (2011)
Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?
Julia U. Holle et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
The American College of Rheumatology 1990 criteria for the classification of wegener's granulomatosis
Randi Y. Leavitt et al.
ARTHRITIS AND RHEUMATISM (2010)
Mycophenolate Mofetil vs Azathioprine for Remission Maintenance in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis A Randomized Controlled Trial
Thomas F. Hiemstra et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2010)
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis.
John H. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Azathioprine or Methotrexate Maintenance for ANCA-Associated Vasculitis.
Christian Pagnoux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis
Bernhard Hellmich et al.
ANNALS OF THE RHEUMATIC DISEASES (2007)
Prevalences of polyarteritis nodosa, microscopic polyangiitis, Wegener's granulomatosis, and Churg-Strauss syndrome in a French urban multiethnic population in 2000:: A capture-recapture estimate
A Mahr et al.
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH (2004)
Observational research methods. Research design II: cohort, cross sectional, and case-control studies
CJ Mann
EMERGENCY MEDICINE JOURNAL (2003)
Share Paper
